Eli Lilly (LLY) showed Omvoh delivered durable efficacy through three years in adults with moderately to severely active Crohn's disease
Importance
Level 1
#ELI LILLY & CO#LLY.US#EQUITIES#EU SESSION#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#ELI LILLY AND CO#LLY#GLOBAL NEWS